Clinical trials
Clinically Significant Prostate Cancer clinical trials
Below are recruiting clinically significant prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 311 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03903835RecruitingPhase 3
Biomarker-guided treatment for metastatic prostate cancer
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
AalstAges 18 years+ - NCT06702995RecruitingPhase 1/Phase 2
Study of XNW5004 plus enzalutamide for advanced prostate cancer
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
Jinan, ShandongAges 18 years+ - NCT07192614RecruitingPhase 1/Phase 2
Study of AZD6621 for men with advanced prostate cancer
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
Orlando, FloridaAges 18 years+ - NCT07168616Recruiting
PSMA PET imaging for active surveillance in low-risk prostate cancer
This study uses a special imaging test (PSMA PET/CT) to better see if men with low-risk prostate cancer are good candidates for active surveillance (monitoring instead of immediate treatment). It helps doctors decide if watching the cancer closely is safe.
Istanbul, TurkeyAges 18 years+ - NCT07156045RecruitingEarly Phase 1
Study of donor NK cells targeting PSMA for advanced prostate cancer
This trial tests a new treatment using natural killer cells from a healthy donor that are designed to find and attack prostate cancer cells that have a protein called PSMA. It may help men with advanced prostate cancer that has stopped responding to hormone therapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT07145177RecruitingPhase 1
Lu177-PSMA with liver treatment for advanced prostate cancer
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
San Francisco, CaliforniaAges 18 years+ - NCT07112781Recruiting
Single dose radiation for early prostate cancer
This trial tests whether a single, high dose of radiation can treat low- to intermediate-risk prostate cancer. It may be a shorter and more convenient option for eligible patients.
MoscowAges 18 years+ - NCT07103018RecruitingPhase 1
Study of KTX-2001 for men with advanced prostate cancer
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
San Francisco, CaliforniaAges 18 years+ - NCT07073794RecruitingPhase 2
Home versus clinic cancer therapy for Black men with prostate cancer
This study looks at whether giving certain prostate cancer treatments at home (instead of the clinic) works as well for Black men. If you qualify, you may get your regular treatment at home with a nurse.
Jacksonville, FloridaAges 18 years+ - NCT07054346RecruitingPhase 1
Radioactive drugs before prostate surgery for high-risk prostate cancer
This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.
San Francisco, CaliforniaAges 18 years+ - NCT07028853RecruitingPhase 3
New drug combo for advanced prostate cancer
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
Huntsville, AlabamaAges 18 years+ - NCT07025369RecruitingPhase 2
Hormone pill before PSMA scan for high-risk prostate cancer
This trial tests if giving a short-term hormone pill (relugolix) before a special PSMA PET/CT scan makes the scan clearer for men with high-risk prostate cancer. It may help doctors better see where the cancer is.
Scottsdale, ArizonaAges 18 years+ - NCT07005154RecruitingPhase 2
Study of ASP5541 for metastatic prostate cancer
This study tests an experimental drug called ASP5541 for men with metastatic prostate cancer (either hormone-sensitive or castration-resistant). It aims to see if the drug can slow cancer growth and improve outcomes when added to standard hormone therapy.
Huntsville, AlabamaAges 18 years+ - NCT07001709RecruitingPhase 4
How abiraterone affects oxycodone in prostate cancer
This study looks at how a common prostate cancer drug (abiraterone) affects how the body processes a painkiller (oxycodone). Men with prostate cancer who take abiraterone will be compared with those who do not, to see if the painkiller works differently.
Deventer, OverijsselAges 18 years+ - NCT05740956RecruitingPhase 1
Drug study for cancers with HRR gene or HRD changes
This Phase 1 study tests HS-10502 in people with advanced solid tumors that have certain DNA repair problems (HRR or HRD). It may help by finding a safe dose and seeing whether the drug can shrink tumors in cancers that have specific genetic features.
Beijing, Beijing MunicipalityAges 18–75 - NCT06915909Recruiting
Robotic prostate surgery with low pressure gas for less pain
This trial tests whether using lower gas pressure during robotic prostate surgery can reduce pain after the operation. It aims to help men recover more comfortably.
Stevenage, HertfordshireAges 18–75 - NCT04004312Recruiting
Short-course radiation slices for localized prostate cancer
This trial tests a radiation approach that delivers treatment in a small number of larger “fractions” (short-course SBRT) for prostate cancer. It may help by targeting the prostate while shortening the overall number of visits.
Montreal, QuebecAges 18 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after prior treatment
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT06738303RecruitingPhase 2
Cabazitaxel with or without carboplatin vs lutetium PSMA for prostate cancer
This trial compares two treatment approaches for advanced prostate cancer that has stopped responding to hormone therapy. One group gets chemotherapy (cabazitaxel with or without carboplatin) and the other gets a targeted radiation therapy (177Lu-PSMA-617). The goal is to see which works better.
Cleveland, OhioAges 19 years+ - NCT06678126RecruitingPhase 2
Adaptive vs standard radiation for prostate cancer
This trial compares two ways of giving radiation to the prostate and pelvic lymph nodes. It also tests two different instructions for how full your bladder should be during treatment. The goal is to see which approach works better and is easier for patients.
Vancouver, British ColumbiaAges 18 years+ - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06568094RecruitingPhase 1/Phase 2
Study of HRS-5041 with other drugs for advanced prostate cancer
This trial tests a new tablet called HRS-5041 combined with other anti-cancer treatments for men with advanced prostate cancer that has not responded to previous therapies. It aims to see how well the combination works and if it is safe.
Harbin, HeilongjiangAges 18–80 - NCT06451445Recruiting
Focal IRE treatment for intermediate-risk prostate cancer
This trial tests a new focal treatment called IRE (irreversible electroporation) that uses electrical pulses to destroy prostate cancer cells while sparing healthy tissue. It is for men with intermediate-risk prostate cancer that has not spread outside the prostate gland.
Toronto, OntarioAges 50 years+
Hear when a new Clinically Significant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinically significant prostate cancer?
- Yes. Clin2 currently lists 311 recruiting clinically significant prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinically significant prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinically significant prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.